CIRCULATING BIOMARKERS IN GASTRIC CANCER PATIENTS TREATED BY HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY
Peritoneal carcinomatosis is detected in more than 30% of patients with advanced gastric cancer (AGC). The development of peritoneal metastases (PM) involves several steps, including detachment of malignant cells and evasion; attachment to and invasion of the peritoneal surface ultimately ending in a colonization phase in which the malignant cells thrive in the newly formed niche. So, several molecules and receptors may be associated with peritoneal dissemination and explore the clinical possibilities of these candidate biomarkers. Thus, the main aim of the presented study was to determine cytokines / growth factors in patients with gastric cancer and to study the effect of intraoperative hyperthermic chemotherapy on it.
Brandl A, Yonemura Y, Glehen O, Sugarbaker P Long term survival in patients with peritoneal metastasised gastric cancer treated with cytoreductive surgery and HIPEC: A multi-institutional cohort from PSOGI. Eur J Surg Oncol. 2021 Jan;47(1):172-180.
de Cuba EM, et al. Angiogenesis-Related Markers and Prognosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer. Ann Surg Oncol. 2016 May;23(5):1601-8.
Duzgun O, et al. Clinical features and surgical outcomes of major urological interventions during cytoreductive surgery and hyperthermic intraperitoneal chemotheraphy. Ther Adv Urol. 2020 Dec 10;12:1756287220975923.
Graziosi L et al. Hyperthermic intraperitoneal chemotherapy as palliative treatment for malignant ascites A single-center experience and a review of the literature. Ann Ital Chir. 2016;87:312-320.
i ZH, et al. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients. Eur J Surg Oncol. 2020 Dec 1 :S0748- 7983(20)31035-0.
Kitai T. The role of cytoreductive surgery and HIPEC in the treatment of peritoneal carcinomatosis: a systematic review including evidence from Japan. Surg Today. 2020 Nov 13. doi: 10.1007/s00595-020-02180-7.
Narayan RR, Poultsides GA. Advances in the surgical management of gastric and gastroesophageal junction cancer. Transl Gastroenterol Hepatol. 2021 Jan 5;6:16.
Pak KH, Park KC, Cheong JH. VEGF-C induced by T GF- a1 signaling in gastric cancer enhances tumor-induced lymphangiogenesis. BMC Cancer. 2019 Aug 13;19(1):799.
Park HS, et al. Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic GC. J Immunother Cancer. 2019 Oct 21;7(1):268.
Passot G, et al. Intraperitoneal vascular endothelial growth factor burden in peritoneal surface malignancies treated with curative intent: the first step before intraperitoneal anti-vascular endothelial growth factor treatment? Eur J Cancer. 2014 Mar;50(4):722-30.
Sluiter NR, et al. Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytorductive surgery and HIPEC. Clin Exp Metastasis. 2016 Apr;33(4):297-307.
Yonemura Y, Iahibashi H, Sako S, Mizumoto A, Takao N, Ichinose M, Motoi S, Liu Y, Wakama S, Kamada Y, Nishihara K. Advances with pharmacotherapy for peritoneal metastasis. Expert Opin Pharmacother. 2020 Nov;21(16):2057- 2066
Yu P, Ye Z, Dai G, Zhang Y, Huang L, Du Y, Cheng X. Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study. BMC Cancer. 2020 Nov 16;20(1):1108.
Zhu L, et al. Prophylactic chemotherapeutic hyperthermic intraperitoneal perfusion reduces peritoneal metastasis in gastric cancer: a retrospective clinical study. BMC Cancer. 2020 Aug 31;20(1):827.
Zou Z, et al. The plasma levels of 12 cytokines and growth factors in patients with gastric cancer. Medicine (Baltimore). 2018 May;97(19):e0413.